Clinical Trials Logo

Clinical Trial Summary

Epilepsy is a disorder of the brain which is associated with disabling seizures and affects 100,000 people under 25. Many children with epilepsy also have a learning disability or problems with development. Although better outcomes occur in children who are successfully treated early for their epilepsy, 25% continue to have seizures despite best medical treatment. One potential treatment is a neurosurgical operation to remove parts of the brain that generate seizures. A proportion of these children have electrodes inserted into their brains as part of their clinical assessment, termed stereoelectroencephalography (SEEG), to help localise these regions. Subsequent surgery is not always successful - up to 40% of children will have ongoing seizures 5 years after surgery. The purpose of this study is to assess the utility of specially designed SEEG electrodes which can measure signals from single brain cells. These electrodes record the same clinical information as normal SEEG electrodes and are implanted in the same way, but can give the research team extra information at the same time. The investigators aim to assess whether studying the changes in the firing of individual cells, both during and between seizures, improves our ability to localise seizures and therefore improve outcomes following surgery. As part of this research project, the investigators will not be doing anything that is not already part of the normal investigation and treatment for these children. Children will be recruited to the study during routine outpatient clinic visits. Surgical planning and execution will not be affected. The electrodes are CE licensed for clinical use and do not alter the risks of the operation. Following the period of monitoring, the care of these children would not be altered in any way. The investigators aim to recruit 30 patients over 3 years. In addition to dissemination via scientific publications and presentations, the findings will be shared with participants and the public.


Clinical Trial Description

Hypothesis The hypothesis is that analysis of ictal (during seizure) and interictal (between seizures) single neuronal firing dynamics will identify ictogenic tissue in children undergoing SEEG recording for focal epilepsy. Study Design Prospective cohort study. Sample Size The investigators will aim to recruit 30 patients over a period of 3 years, of which 50% will have a normal MRI and 50% will have an identifiable lesion. It is not possible to conduct specific sample size calculations for this study but the centre carries out approximately 24 SEEG recordings per year so this target is feasible and achievable. Participant Journey The current patient pathway for children with medically refractory epilepsy undergoing pre-surgical evaluation will not be altered by the current study. The suitability for SEEG recording will be determined by the specialist epilepsy multidisciplinary team (MDT) and patients and parents will be invited to the neurosurgical outpatient clinic to discuss the procedure. There is nothing additional that will be required as part of this research study. If they agree to proceeding with the SEEG recording procedure, patients will be invited to participate in this study during routine outpatient clinic visits. The treating consultant neurosurgeon (who is part of the routine clinical care team) will inform the patients and parents about the study and give them the opportunity to meet with the clinical research fellow. Patients and their parents will have the study explained to them by the research fellow and be given age-specific information sheets. Following an adequate time to digest this information (a few weeks) and an opportunity to ask any questions, the child (if appropriate) and their parents will choose whether or not they wish to participate in the research. If they choose to participate they will be asked to give written informed consent. The novel combined micro-macro electrodes will then be used during the surgical implantation procedure. The use of these novel electrodes will not change the surgical procedure, which is conducted using robotic assistance to ensure optimal accuracy. The macro electrode recordings will be used for routine clinical analysis and the duration of recording and subsequent analysis of the recordings will not be affected by the micro electrode data captured for research purposes. The clinical SEEG also involves electrical stimulation of the brain which will not be affected by the study. Participation in this study will not preclude participation in these other studies and it may be possible to use the micro electrode data to supplement analyses in these other studies. Subsequent decision making on suitability for a surgical procedure will follow the normal clinical pathway and will not be affected by the micro electrode recording data. Further participant follow-up will be observational and data will be obtained from routinely available clinical information, including whether or not a surgical resection is carried out and, if so, whether the patient remains seizure-free at follow-up. The pseudo-anonymised research data will be securely stored via a secure university (UCL) research data storage service in a safe haven. Data will be stored for the duration of the study and 15 years following completion of the study to comply with GOSH guidelines. Data will be analysed according to the pre-specified data analysis plan, outlined elsewhere in this application. Timeline - February 2019 - April 2019 (3 months): Study and infrastructure set-up including acquisition of appropriate recording amplifiers and finalisation of data storage arrangements. - May 2019 - July 2021 (2 years 3 months): Recruitment. Aim to recruit 15 patients per year. Sufficient provision to allow for slow recruitment in the timeline to ensure that adequate sample is achieved for subsequent analysis. - August 2021 - October 2021 (3 months): Data analysis. - November 2021 - January 2022 (3 months): Write-up and dissemination of results. The scientific results will be disseminated in the form of peer-reviewed publications & conference presentations. In addition, sessions will be held to disseminate the results to patients and the public, in the form of information evenings to groups such as Young Epilepsy and Epilepsy Action. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03916848
Study type Interventional
Source Great Ormond Street Hospital for Children NHS Foundation Trust
Contact
Status Active, not recruiting
Phase N/A
Start date June 16, 2019
Completion date April 2022

See also
  Status Clinical Trial Phase
Terminated NCT00524030 - Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures Phase 3
Completed NCT00143143 - Pregabalin Open-Label Extension Trial in Patients With Partial Seizures Phase 3
Completed NCT00771927 - Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures N/A
Completed NCT00236873 - A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures. Phase 2
Completed NCT01745952 - Treatment of Difficult to Control Focal Epilepsy With Repetitive Transcranial Magnetic Stimulation (rTMS) N/A
Completed NCT00772603 - Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures Phase 3
Completed NCT00280696 - A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures Phase 3
Completed NCT00643136 - A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures Phase 3
Completed NCT00230698 - A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure Phase 3
Completed NCT00072813 - MRI in Autosomal Dominant Partial Epilepsy With Auditory Features N/A
Enrolling by invitation NCT04309812 - Transcranial Direct Current to Treat Epilepsy at Home Early Phase 1
Completed NCT00620555 - A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures Phase 3
Withdrawn NCT00422110 - A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures Phase 2/Phase 3
Completed NCT00448916 - Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures Phase 3
Completed NCT00210522 - An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy Phase 2
Completed NCT00236886 - Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients Phase 3
Completed NCT00236860 - A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures Phase 2
Active, not recruiting NCT03689114 - Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) Phase 4
Completed NCT01098162 - Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug N/A
Completed NCT05273398 - Effects of Diazepam on RNS Detections Phase 4